• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The AMPLIFY trial: Apixaban for treatment of venous thromboembolism [Classics Series]

byAndrew Cheung, MD MBA
January 12, 2015
in Emergency Classics, General Medicine Classics, Surgery Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Apixaban was found to be non-inferior to conventional therapy (i.e., enoxaparin followed by warfarin) in the treatment of acute venous thromboembolism.

2. Major bleeding was found to be significantly less common in patients treated with apixaban as compared with conventional therapy.

Original Date of Publication: August 2013

Study Rundown: New oral anticoagulants are being increasingly used for a number of different indications, including stroke prophylaxis in patients with atrial fibrillation and treatment of venous thromboembolic disease. The purpose of the Apixiban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial was to determine if apixaban, an oral factor Xa inhibitor, would be non-inferior to conventional therapy (i.e., enoxaparin followed by warfarin) for the treatment of acute venous thromboembolic disease. In summary, apixaban was found to be non-inferior to conventional therapy in preventing recurrent venous thromboembolism or death from venous thromboembolism. The rate of major bleeding was found to be significantly lower in patients treated with apixaban as compared with conventional therapy. Of note, the study was funded Bristol-Myers Squibb and Pfizer, and employees of Pfizer were involved in numerous stages of the study’s design and conduct.

Click to read study in NEJM

In-Depth [randomized controlled trial]: This randomized, non-inferiority trial was conducted at 358 centres in 28 countries. A total of 5,400 patients were enrolled and randomized to treatment with apixaban or conventional therapy (i.e., enoxaparin for 5 days and warfarin for 6 months with target INR between 2-3). Patients were included in the trial if they were >18 years of age, had objectively confirmed proximal deep-vein thrombosis (DVT) and/or pulmonary embolism. Exclusion criteria included active bleeding, a high risk of bleeding, other contraindications to anticoagulation, cancer, provoked venous thromboembolic disease, dual antiplatelet therapy, and creatinine clearance <25 mL/min. The primary efficacy outcome was a composite of recurrent symptomatic venous thromboembolism or death from venous thromboembolism. Secondary outcomes included each component of the primary outcome, in addition to cardiovascular mortality and all-cause mortality. The primary safety outcome was major bleeding. Notably, the trial was sponsored by Bristol-Myers Squibb and Pfizer. Moreover, the steering committee included employees of Pfizer, who were involved in study design, study oversight, data verification and analysis, and manuscript writing.

There was no difference in the rate of the primary outcome in the two groups (RR 0.84; 95%CI 0.60-1.18) and the findings met criteria for non-inferiority. Moreover, there were no significant differences between the groups in terms of the risk of cardiovascular or all-cause mortality. Major bleeding occurred significantly less frequently in patients treated with apixaban compared to those on conventional therapy (RR 0.31; 95%CI 0.17-0.55).

RELATED REPORTS

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

Rivaroxaban associated with significantly increased risk of major ischemic or hemorrhagic events versus apixaban in patients with atrial fibrillation

#VisualAbstract Vitamin K antagonists did not increase the risk of myelodysplastic syndrome in patients with non-valvular atrial fibrillation

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: apixabandvt
Previous Post

Standardized measures effectively tracked psoriasis and acne outcomes

Next Post

Use of injectable contraceptive, Depo-Provera, linked to increased risk of HIV

RelatedReports

Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

April 19, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Cardiology

Rivaroxaban associated with significantly increased risk of major ischemic or hemorrhagic events versus apixaban in patients with atrial fibrillation

December 22, 2021
#VisualAbstract Vitamin K antagonists did not increase the risk of myelodysplastic syndrome in patients with non-valvular atrial fibrillation
StudyGraphics

#VisualAbstract Vitamin K antagonists did not increase the risk of myelodysplastic syndrome in patients with non-valvular atrial fibrillation

August 12, 2021
Peri-operative interruption of DOACs associated with low rates of bleeding and thrombosis
Cardiology

Peri-operative interruption of DOACs associated with low rates of bleeding and thrombosis

August 12, 2019
Next Post
Use of injectable contraceptive, Depo-Provera, linked to increased risk of HIV

Use of injectable contraceptive, Depo-Provera, linked to increased risk of HIV

Fluorophores enhance visualization for image-guided surgery [PreClinical]

Fluorophores enhance visualization for image-guided surgery [PreClinical]

Tumor size, chemoembolization response may predict hepatocellular carcinoma recurrence

MRI superior to CT for liver cancer diagnosis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.